Bioimpedance as a Tool for Fluid Management in Peritoneal Dialysis (PD) Patients
NCT ID: NCT00801112
Last Updated: 2008-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2009-01-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives of the study: The objective is to show that in patients where the additional information of body composition is available to the clinician that the ECFv is maintained within pre-agreed limits, \~ 1 liter, over the observation period of 12 months.
SCIENTIFIC BACKGROUND:
Low peritoneal ultrafiltration, and by inference low sodium removal, is associated with worse outcomes in PD. Equally, excessive fluid removal is a risk factor for dehydration and loss of residual renal function. Current guidelines have advocated a daily UF volume of 1litre; their blunt application could lead to either inappropriate early loss of residual function or modality transfer. There is a significant need for evidence on how to best manage fluid status in PD patients, both in terms of an appropriate clinical strategy and also a simple but reproducible tool to guide clinicians in how to apply this strategy.
It is likely that BIA will become the standard tool to aid clinicians in assessing fluid status. It is simple to perform, intervention studies have demonstrated its ability to identify changes in fluid status in response to changes in therapy and it is a powerful predictor of patient survival. There is, however a clear need at this stage for proof of principle studies to establish its true potential for added value in the routine management of patients.
Body composition changes spontaneously with time on PD. Short term changes in hydration (specifically extracellular fluid volume, ECFv) combined with medium term changes in muscle and fat make it difficult for the clinician to be sure if fluid status is stable. It is anticipated that regular BIA measurements will aid the clinician in managing this problem over and above monitoring of weight and fluid status. By randomizing patients into two groups who have regular BIA measurements, one of which the BIA data is available to the clinician it will be possible to see if these spontaneous changes in body composition can be accounted for.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
PD patients with residual renal function \>200ml with BIA monitor.
No interventions assigned to this group
2
PD patients with residual renal function \<200ml with BIA monitor.
No interventions assigned to this group
3
PD patients with residual renal function \>200ml without BIA monitor
No interventions assigned to this group
4
PD patients with residual renal function \<200ml without BIA monitor
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who are unable to give consent.
* Patients who have peritonitis the last 30 days prior to study enrollment.
* Patients who are pregnant.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. James's Hospital, Ireland
OTHER
Sheffield Teaching Hospitals NHS Foundation Trust
OTHER
University Hospital of North Staffordshire
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital of North Staffordshire
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simon J Davies, MD FRCP
Role: PRINCIPAL_INVESTIGATOR
University Hospital of North Staffordshire
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of North Staffordshire
Stoke-on-Trent, Staffordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Simon J Davies, MD FRCP
Role: primary
Kay B Tan, MB MRCP
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIA-001MC
Identifier Type: -
Identifier Source: org_study_id